BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 19308670)

  • 21. [The development of cognitive functions in children with Hurler phenotype mucopolysaccharidosis type I on enzyme replacement therapy with laronidase].
    Biernacka M; Jakubowska-Winecka A; Tylki-Szymańska A
    Pediatr Endocrinol Diabetes Metab; 2010; 16(4):249-54. PubMed ID: 21447265
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years.
    Sifuentes M; Doroshow R; Hoft R; Mason G; Walot I; Diament M; Okazaki S; Huff K; Cox GF; Swiedler SJ; Kakkis ED
    Mol Genet Metab; 2007 Feb; 90(2):171-80. PubMed ID: 17011223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ocular lesions in canine mucopolysaccharidosis I and response to enzyme replacement therapy.
    Newkirk KM; Atkins RM; Dickson PI; Rohrbach BW; McEntee MF
    Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5130-5. PubMed ID: 21436264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes of Long-Term Treatment with Laronidase in Patients with Mucopolysaccharidosis Type I.
    Laraway S; Mercer J; Jameson E; Ashworth J; Hensman P; Jones SA
    J Pediatr; 2016 Nov; 178():219-226.e1. PubMed ID: 27788836
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Laronidase replacement therapy improves myocardial function in mucopolysaccharidosis I.
    Harada H; Uchiwa H; Nakamura M; Ohno S; Morita H; Katoh A; Yoshino M; Ikeda H
    Mol Genet Metab; 2011 Jul; 103(3):215-9. PubMed ID: 21482163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of anti-laronidase antibodies on efficacy and safety of laronidase enzyme replacement therapy for MPS I: A comprehensive meta-analysis of pooled data from multiple studies.
    Xue Y; Richards SM; Mahmood A; Cox GF
    Mol Genet Metab; 2016 Apr; 117(4):419-26. PubMed ID: 26920513
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarker responses correlate with antibody status in mucopolysaccharidosis type I patients on long-term enzyme replacement therapy.
    Langereis EJ; van Vlies N; Church HJ; Geskus RB; Hollak CE; Jones SA; Kulik W; van Lenthe H; Mercer J; Schreider L; Tylee KL; Wagemans T; Wijburg FA; Bigger BW
    Mol Genet Metab; 2015 Feb; 114(2):129-37. PubMed ID: 25467058
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternative laronidase dose regimen for patients with mucopolysaccharidosis I: a multinational, retrospective, chart review case series.
    Horovitz DD; Acosta AX; Giugliani R; Hlavatá A; Hlavatá K; Tchan MC; Lopes Barth A; Cardoso L; Embiruçu de Araújo Leão EK; Esposito AC; Kyosen SO; De Souza CF; Martins AM
    Orphanet J Rare Dis; 2016 Apr; 11(1):51. PubMed ID: 27129473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.
    Dierenfeld AD; McEntee MF; Vogler CA; Vite CH; Chen AH; Passage M; Le S; Shah S; Jens JK; Snella EM; Kline KL; Parkes JD; Ware WA; Moran LE; Fales-Williams AJ; Wengert JA; Whitley RD; Betts DM; Boal AM; Riedesel EA; Gross W; Ellinwood NM; Dickson PI
    Sci Transl Med; 2010 Dec; 2(60):60ra89. PubMed ID: 21123810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucopolysaccharidosis I presenting with endocardial fibroelastosis of infancy.
    Stephan MJ; Stevens EL; Wenstrup RJ; Greenberg CR; Gritter HL; Hodges GF; Guller B
    Am J Dis Child; 1989 Jul; 143(7):782-4. PubMed ID: 2500843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).
    Wraith JE; Clarke LA; Beck M; Kolodny EH; Pastores GM; Muenzer J; Rapoport DM; Berger KI; Swiedler SJ; Kakkis ED; Braakman T; Chadbourne E; Walton-Bowen K; Cox GF
    J Pediatr; 2004 May; 144(5):581-8. PubMed ID: 15126990
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).
    Wraith JE; Beck M; Lane R; van der Ploeg A; Shapiro E; Xue Y; Kakkis ED; Guffon N
    Pediatrics; 2007 Jul; 120(1):e37-46. PubMed ID: 17606547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy in 12 patients with MPS I-H/S with homozygous p.Leu490Pro mutation.
    Arora RS; Mercer J; Thornley M; Tylee K; Wraith JE
    J Inherit Metab Dis; 2007 Oct; 30(5):821. PubMed ID: 17570076
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of rehabilitation in Hurler's syndrome.
    Mishra SR; Shastri M; Ramesh J
    J Back Musculoskelet Rehabil; 2017; 30(3):635-639. PubMed ID: 27911282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laronidase.
    BioDrugs; 2002; 16(4):316-8. PubMed ID: 12196045
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.
    Wraith JE
    Expert Opin Pharmacother; 2005 Mar; 6(3):489-506. PubMed ID: 15794739
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease.
    Hsu YH; Liu RS; Lin WL; Yuh YS; Lin SP; Wong TT
    Orphanet J Rare Dis; 2017 Jun; 12(1):109. PubMed ID: 28595620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis.
    Dualibi AP; Martins AM; Moreira GA; de Azevedo MF; Fujita RR; Pignatari SS
    Braz J Otorhinolaryngol; 2016; 82(5):522-8. PubMed ID: 26750310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Left ventricular aneurysm in an adult patient with mucopolysaccharidosis type I: comment on pathogenesis of a novel complication.
    Cabrera GH; Fernández I; Dominguez M; Clarke LA
    Mol Genet Metab; 2012 Aug; 106(4):470-3. PubMed ID: 22732207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzyme replacement therapy in feline mucopolysaccharidosis I.
    Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
    Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.